Page last updated: 2024-11-08

norlevorphanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID519103
CHEMBL ID42629
SCHEMBL ID13383458
MeSH IDM0153001

Synonyms (15)

Synonym
norlevorphanol
morphinan-3-ol
CHEMBL42629
(+)-3-hydroxymorphinan hydrobromide
SCHEMBL13383458
IYNWSQDZXMGGGI-UHFFFAOYSA-N
(+)-morphinan-3-ol
9.alpha.,13.alpha.,14.alpha.-morphinan-3-ol
Q7051399
AS-6181
us11535596, compound cns1-d5
bdbm587516
AKOS037645618
17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
DTXSID60862686

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, the bioavailability of 3-HM is very low due to the rapid first-pass metabolism of the phenolic moiety."( Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of 3-Hydroxymorphinan.
Bai, X; Bao, X; Li, Z; Shang, J; Sheng, C; Wang, J; Wang, Y; Zhang, D; Zhang, G; Zhu, M, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The direction of dosing adjustments during pregnancy will depend on the drug and the enzyme that is responsible for its metabolism."( Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
Caritis, SN; Glover, DD; Tracy, TS; Venkataramanan, R, 2005
)
0.33
"Ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-QToF-MS) analysis of dextromethorphan (DXM) and its metabolites-dextrorphan, 3-methoxymorphinan (3-MEM) and 3-hydroxymorphinan-in skeletal remains of rats exposed to DXM under different dosing patterns is described."( Analysis of Dextromethorphan and Three Metabolites in Decomposed Skeletal Tissues by UPLC-QToF-MS: Comparison of Acute and Repeated Drug Exposures.
Cornthwaite, HM; McDonald, CS; Watterson, JH, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID170083The compound was examined for circling behavior (marginal activity) using automated videotracking system 30 min after intraperitoneal injection at the dose of 40 mg/Kg in 12 rats2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Anticonvulsant effects of new morphinan derivatives.
AID170082The compound was examined for circling behavior (marginal activity) using automated videotracking system 30 min after intraperitoneal injection at the dose of 20 mg/Kg in 12 rats2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Anticonvulsant effects of new morphinan derivatives.
AID184525Effect was expressed as mortality after injection of kainic acid (10 mg/kg) and the drug at the dose of 40 mg/Kg after 48 hr2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Anticonvulsant effects of new morphinan derivatives.
AID196181The compound was tested for anticonvulsive activity expressed as seizure score after 4 hr of injection of kainic acid (10 mg/kg) and the drug at the dose of 20 mg/Kg in 15 rats2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Anticonvulsant effects of new morphinan derivatives.
AID184524Effect was expressed as mortality after injection of kainic acid (10 mg/kg) and the drug at the dose of 20 mg/Kg after 48 hr out of 19 animals2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Anticonvulsant effects of new morphinan derivatives.
AID196182The compound was tested for anticonvulsive activity expressed as seizure score after 4 hr of injection of kainic acid (10 mg/kg) and the drug at the dose of 40 mg/Kg in 15 rats2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Anticonvulsant effects of new morphinan derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (16.67)18.7374
1990's5 (16.67)18.2507
2000's16 (53.33)29.6817
2010's3 (10.00)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.50 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (9.68%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]